BAML-16-001-S24: Phase 1b safety run-in study followed by Phase 2 study of Ficlatuzumab, Azacitidine and Venetoclax in Untreated Acute Myeloid Leukemia (AML) patients aged >=60 years old
- Title
- Phase 1b safety run-in study followed by Phase 2 study of Ficlatuzumab, Azacitidine and Venetoclax in Untreated Acute Myeloid Leukemia (AML) patients aged >=60 years old
- Principal Investigator
- Bhatnagar, Bhavana
- Phase
- I/II (Cancer Control)
- Age Group
- Adult
- Applicable Disease Sites
- Leukemia
- Participating Institutions
- Mary Babb Randolph Cancer Center
- Contacts
- Maher Kali, MD
- Clinical Research Specialist-WVUCI
- Phone: +1 304-243-7045
- Email: maher.kali@wvumedicine.org
- Syed Abdul Mannan Shah
- Clinical Research Specialist
- Phone: +1 304-293-1683
- Email: syedabdulmannan.shah@hsc.wvu.edu
- Autumn Borovich
- Research Assistant
- Email: autumn.borovich@wvumedicine.org